Immuneering (NASDAQ:IMRX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.08), FiscalAI reports.
Immuneering Price Performance
IMRX traded up $0.03 during trading on Thursday, reaching $4.02. 774,377 shares of the stock traded hands, compared to its average volume of 772,644. The stock’s 50-day simple moving average is $4.34 and its two-hundred day simple moving average is $4.80. Immuneering has a fifty-two week low of $3.38 and a fifty-two week high of $8.48.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of IMRX. Integrated Wealth Concepts LLC acquired a new stake in shares of Immuneering during the 2nd quarter valued at about $34,000. Levin Capital Strategies L.P. bought a new stake in shares of Immuneering in the 1st quarter valued at approximately $53,000. VestGen Advisors LLC increased its holdings in Immuneering by 100.0% in the third quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock worth $82,000 after buying an additional 10,002 shares during the last quarter. Focus Financial Network Inc. acquired a new position in Immuneering in the second quarter worth approximately $62,000. Finally, Cetera Investment Advisers acquired a new position in Immuneering in the first quarter worth approximately $67,000. 67.65% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
IMRX has been the subject of several recent analyst reports. UBS Group set a $14.00 target price on Immuneering in a research report on Thursday, August 6th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Chardan Capital raised Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. Needham & Company LLC increased their price objective on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Cantor Fitzgerald started coverage on Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.57.
Read Our Latest Research Report on IMRX
About Immuneering
Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.
Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.
See Also
- Five stocks we like better than Immuneering
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
